--- title: 'Director, Medical Science Liaisons at Praxis Precision Medicines, Inc.' canonical: 'https://feeny.ai/job/director-medical-science-liaisons-praxis-precision-medicines-inc-united-states-bhakzbah9dvw' type: 'job' last_seen: '2026-09-13' --- # Director, Medical Science Liaisons at Praxis Precision Medicines, Inc. - **Company:** Praxis Precision Medicines, Inc. - **Location:** United States - **Compensation:** $228k–$248k - **Work type:** remote - **Posted:** 2026-08-26 - **Last confirmed live:** 2026-09-13 - **Apply:** https://job-boards.greenhouse.io/praxisprecisionmedicines/jobs/5399693008 ## Job description Position Summary Praxis is seeking a Director, Field Medical – Movement Disorders to lead a team of Medical Science Liaisons (MSLs) supporting Medical Affairs activities for ulixacaltimide in essential tremor. This is a hands-on, field-facing leadership role for someone who can build and develop a high-performing MSL team while remaining directly engaged with priority scientific and clinical stakeholders. This role will report directly to the Head of Field Medical Affairs. Reporting to the Head of Field Medical Affairs, the Director will translate Medical Affairs strategy into focused field execution, strengthen scientific engagement, and ensure high-quality field insights inform medical and cross-functional decisions. This role will partner closely with Medical Affairs, Clinical Development, Commercial, and Market Access while maintaining appropriate Medical Affairs independence and compliance standards. Primary Responsibilities - Lead and develop a high-performing MSL team, setting clear expectations for scientific excellence, stakeholder engagement, insight generation, accountability, and results. Provide hands-on coaching through regular field visits, joint engagements, feedback, and individualized development. - Operate as a player-coach, maintaining direct, trusted scientific relationships with priority academic and community neurologists, movement disorder specialists, investigators, advanced practice providers, and other relevant stakeholders. - Translate Medical Affairs strategy into focused field execution, including regional stakeholder planning, strategic account planning, resource deployment, and pre-launch, potential launch, and post-launch priorities for essential tremor. - Drive high-quality scientific exchange and external engagement around essential tremor, emerging clinical data, treatment paradigms, and the evolving therapeutic landscape, including support for advisory boards, congresses, and scientific meetings. - Turn field intelligence into action by identifying and synthesizing emerging scientific questions, unmet needs, changes in clinical practice, patient-care barriers, and other insights that can shape Medical Affairs and broader cross-functional strategy. - Partner effectively across the organization, including with Medical Affairs, Clinical Development, Commercial, and Market Access. Provide scientific and clinical context on disease burden, patient journeys, treatment pathways, evidence needs, and access considerations while maintaining appropriate functional boundaries. - Build an effective, accountable, and compliant field organization by supporting recruitment, onboarding, training, performance management, field effectiveness, launch readiness, resource planning, and adherence to regulatory requirements, industry standards, company policies, and Praxis SOPs. ## Qualifications and Key Success Factors - Advanced clinical or scientific degree (PharmD, PhD, MD, NP, PA, RN, or equivalent). - Prior MSL experience with demonstrated success in field-based Medical Affairs. - Demonstrated people leadership, including the ability to coach, develop, and hold a field-based team accountable while maintaining strong scientific credibility. - Experience in neurology or CNS disorders required; movement disorders experience, including essential tremor or Parkinson’s disease, preferred. - Pre-launch and/or launch Medical Affairs experience strongly preferred. - Ability to rapidly build deep therapeutic expertise, translate complex scientific and clinical information into field strategy, and engage credibly with external experts. - Strong strategic judgment, account planning, insight generation, and cross-functional collaboration skills. - Experience partnering with Market Access and understanding payer and access considerations preferred. - High ownership and comfort operating with autonomy and ambiguity in a fast-moving environment; able to prioritize what matters and drive execution. - Demonstrated ability to build trusted relationships with healthcare professionals, investigators, and external scientific experts. - Willingness and ability to travel extensively based on business needs. The physical and mental requirements of our roles include but are not limited to regular use of a computer, devices or other office equipment, clear communication, and occasional movement. You'll need comfort with screen work, basic hand coordination, and focus. Reasonable accommodations may be made to enable individuals with disabilities to perform these functions. Annualized Base Salary $228,000—$248,000 USD ## Compensation & Benefits At Praxis, we believe that taking care of our people (and their people) is important, so we provide a world class benefits package to help you thrive.  This includes 99% of the premium paid for medical, dental and vision plans.  We also provide company-paid life insurance, AD&D, disability benefits, and voluntary plans to personalize your coverage. Thinking about the future?  We match dollar-for-dollar up to 6% on eligible 401(k) contributions and sweeten the deal with long-term stock incentives and ESPP.  We provide a discretionary quarterly bonus, an extremely flexible wellness benefit, generous PTO, paid holidays and company-wide shutdowns.  Not to mention, you'll also be joining a phenomenal crew of colleagues who are smart, engaged and inspiring.  We aim high, collaborate hard, and produce results.  Let’s achieve the impossible together! Company Overview Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.  At Praxis we share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders.  Our core Values of Trust, Ownership, Curiosity and Results are foundational to every aspect of our business and are exemplified by each and every one of our team members. Diversity, Equity & Inclusion Guided by our core values, at Praxis Precision Medicines, Inc. we continue to DARE FOR MORE® to advance, promote, and champion diversity, equity, and inclusion by encouraging individuals to bring their authentic selves and perspectives to work each day. We are an equal opportunity employer and committed to providing opportunities to all qualified applicants without regard to race, religious creed, color, gender identity or expression, age, national origin, sexual orientation, disability, genetics, military service and veteran status, or any other characteristic protected by federal, state, or local laws. Attention: Job Scam Alert Praxis has recently become aware of fraudulent job recruitment postings from individuals claiming to represent Praxis. These postings seek financial information in connection with fraudulent opportunities for employment. If you suspect any fraudulent activity or misrepresentation in connection with a Praxis job opportunity, please report it to careers@praxismedicines.com. Praxis does not accept unsolicited submissions from recruitment agencies for open positions. We ask all recruitment agencies to refrain from contacting any Praxis employee regarding any position. All unsolicited resumes submitted by recruitment agencies to any Praxis employee in any form or method will be deemed to be the property of Praxis, and Praxis explicitly reserves the right to hire those candidate(s) without any financial obligation to the recruitment agency. ## About Praxis Precision Medicines, Inc. ## Company Overview - **One-liner**: Praxis Precision Medicines is a fully integrated, clinical-stage biopharmaceutical company developing precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. - **Entity Type**: Public (NASDAQ: PRAX) - **Headquarters**: Boston, Massachusetts, United States - **Founded**: 2015 - **Founders**: Dr. Steven Petrou (Co-Founder and President of R&D) ## Core Business - **Primary Industry**: Biotechnology (CNS / Neuroscience) - **Target Customers**: Patients with rare and prevalent neurological disorders (e.g., essential tremor, developmental and epileptic encephalopathies, focal epilepsy); healthcare providers; payers. - **Mission / Purpose**: To translate genetic insights into the development of life-altering therapies for CNS disorders more effectively and efficiently. ## Products & Services Praxis operates two proprietary platforms and a pipeline of late-stage and early-stage programs: - **Cerebrum™ (Small Molecule Platform)**: Orally available precision therapies targeting ion channels and neuronal circuits. Key assets include: - **Ulixacaltamide**: A T-type calcium channel inhibitor for essential tremor (ET). NDA submission to the FDA expected by mid-February 2026. Breakthrough Therapy Designation. - **Relutrigine**: For SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEEs). NDA submission expected by mid-February 2026. Breakthrough Therapy Designation. Also in Phase 3 for broad DEEs. - **Vormatrigine**: A sodium-channel modulator for focal onset seizures (FOS). In Phase 3 trials (POWER1, POWER2). - **Solidus™ (Antisense Oligonucleotide Platform)**: For genetically defined CNS disorders. Key asset: - **Elsunersen**: An ASO designed to reduce SCN2A gene expression for early-seizure-onset SCN2A-DEE. In Phase 3 (EMBRAVE3). Orphan Drug Designation. - **Early-Stage Pipeline**: Preclinical candidates (PRAX-020, PRAX-080, PRAX-090, PRAX-100) targeting other genetic epilepsies and neurodevelopmental disorders. ## Market Standing - **Market Cap**: ~$156.0 million (as of mid-2026 data) [linkedin.com] - **Key Metric (Revenue/Funding)**: Annual revenue reported at ~$8.6M (pre-commercial stage). Pro forma cash, cash equivalents, and marketable securities stand at **$1.5 billion** following a public offering in January 2026 that raised ~$621 million [ir.praxismedicines.com]. - **Notable Investors/Partners**: Ionis Pharmaceuticals, Inc. (collaboration on elsunersen); RogCon, Inc. (license agreement). - **Growth Signals**: - Rapidly scaling headcount: 166 employees (+49.7% year-over-year) [linkedin.com]. - Transformation to a commercial-stage company: Preparing for two NDA submissions by mid-February 2026. - Combined peak revenue estimates for its four late-stage assets expected to exceed **$20 billion** [ir.praxismedicines.com]. - Active hiring: 31 open positions in mid-2026 (up 933% year-over-year) [linkedin.com]. ## Competitive Advantages - **Precision Neuroscience Moat**: Deep understanding of shared biological targets and circuits in the brain derived from genetic epilepsies. - **Proprietary Dual Platforms**: Leveraging both small molecule (Cerebrum) and ASO (Solidus) modalities to address a wide range of CNS disorders. - **Breakthrough Therapy Designations**: Both lead assets (ulixacaltamide, relutrigine) have FDA Breakthrough Therapy Designation, accelerating development and review. - **Strong Cash Position**: $1.5 billion pro forma cash provides a long runway through multiple potential product launches and pipeline expansion. - **Late-Stage Pipeline**: Four late-stage product candidates approaching potential commercial launch, de-risking the company substantially. ## Strategic Focus - **Commercial Launch Readiness**: Building out commercial infrastructure, sales force, and patient support programs in parallel with regulatory submissions. - **Pipeline Expansion**: Declaring multiple new drug candidates from both Cerebrum and Solidus platforms in 2026. - **Lifecycle Management**: Exploring indication expansion for existing assets (e.g., relutrigine in broad DEEs via the EMERALD study; vormatrigine for monotherapy FOS). - **Global Reach**: Operating in 5 countries (US, Australia, India, Colombia, Brazil) with a growing workforce. ## Why Work Here - **Mission-Driven Work**: Opportunity to deliver transformative therapies to patients with severe, underserved CNS disorders. - **Growth Trajectory**: The company is at a pivotal inflection point, transitioning from a clinical-stage to a commercial-stage organization — offering dynamic career growth. - **Remote-First Culture**: The vast majority of open positions across all departments (Clinical, Medical, Commercial, Finance, Legal, etc.) are listed as **"United States - Remote"** [greenhouse.io]. This includes roles like Director, Commercial Compliance; Senior Clinical Trial Manager; and Director, Field Reimbursement. - **Global Talent**: Engineering and technical roles are open internationally (e.g., Software Engineer in Brazil) [greenhouse.io]. - **Strong Leadership**: Recent appointments of experienced pharmaceutical executives (Jeffrey B. Kinder, Stuart Arbuckle) and internal promotions (Megan Sniecinski to COO). - **Compensation**: Employee reviews indicate a strong **Compensation rating of 4.0/5.0**, though overall culture and career ratings are lower (2.8 and 2.7 respectively on LinkedIn) [linkedin.com]. - **Workforce Demographics**: A high proportion of Director-level roles are open (20% of workforce), alongside specialists and senior IC roles, suggesting significant opportunities for leadership-level hires. ## Sources 1. [greenhouse.io](http://job-boards.greenhouse.io/praxisprecisionmedicines) - Jobs at Praxis Precision Medicines, Inc. 2. [ir.praxismedicines.com](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-enters-its-next-chapter-following) - Press Release: Business Outlook and Priorities for 2026 3. [linkedin.com](https://www.linkedin.com/company/praxis-precision-medicines-inc) - LinkedIn Company Profile 4. [stockanalysis.com](https://stockanalysis.com/stocks/prax/company/) - Company Profile & Key Executives ## Other roles at Praxis Precision Medicines, Inc. - [Corporate Counsel - US](https://feeny.ai/job/corporate-counsel-us-praxis-precision-medicines-inc-united-states-3pawyte701ph) — United States - [Associate Director, Regulatory Affairs, AD Promo](https://feeny.ai/job/associate-director-regulatory-affairs-ad-promo-praxis-precision-medicines-inc-knjtsbdgq5rn) — United States - [Medical Information Specialist](https://feeny.ai/job/medical-information-specialist-praxis-precision-medicines-inc-united-states-p7f0w7ye8d61) — United States - [Clinical Medical Monitor](https://feeny.ai/job/clinical-medical-monitor-praxis-precision-medicines-inc-united-states-aycaavkze79q) — United States - [Manager, Analytical Sciences - Commercial](https://feeny.ai/job/manager-analytical-sciences-commercial-praxis-precision-medicines-inc-united-fj5ctas3k0w2) — United States - [Associate Director, Regulatory CMC](https://feeny.ai/job/associate-director-regulatory-cmc-praxis-precision-medicines-inc-united-states-e2y1dazam5bd) — United States - [Computer Systems Validation Engineer](https://feeny.ai/job/computer-systems-validation-engineer-praxis-precision-medicines-inc-united-84kqsazb917h) — United States - [Clinical Development Leader, Lifecycle Management](https://feeny.ai/job/clinical-development-leader-lifecycle-management-praxis-precision-medicines-inc-hvv6gtsjkytp) — United States - [Clinical Development Leader, Epilepsies](https://feeny.ai/job/clinical-development-leader-epilepsies-praxis-precision-medicines-inc-united-ywq6h858ygqj) — United States - [Clinical Development Leader, Movement Disorders](https://feeny.ai/job/clinical-development-leader-movement-disorders-praxis-precision-medicines-inc-ysgcsw94ftfc) — United States